TETRAAMMINECOPPER SULFATE MONOHYDRATE

First marketed in 1921

Details

Stereochemistry	ACHIRAL
Molecular Formula	Cu.O4S.H2O.4H3N
Molecular Weight	245.746
Optical Activity	NONE
Defined Stereocenters	0 / 0
E/Z Centers	0
Charge	0

SHOW SMILES / InChI

Structure of TETRAAMMINECOPPER SULFATE MONOHYDRATE

Structure Search

SMILES

N.N.N.N.O.[Cu++].[O-]S([O-])(=O)=O

InChI

InChIKey=ABAHXVHZPFQSDZ-UHFFFAOYSA-L

InChI=1S/Cu.4H3N.H2O4S.H2O/c;;;;;1-5(2,3)4;/h;4*1H3;(H2,1,2,3,4);1H2/q+2;;;;;;/p-2

HIDE SMILES / InChI

Molecular Formula	HO4S
Molecular Weight	97.071
Charge	-1
Count

Stereochemistry	ACHIRAL
Additional Stereochemistry	No
Defined Stereocenters	0 / 0
E/Z Centers	0
Optical Activity	NONE

Molecular Formula	H3N
Molecular Weight	17.0305
Charge	0
Count

Stereochemistry	ACHIRAL
Additional Stereochemistry	No
Defined Stereocenters	0 / 0
E/Z Centers	0
Optical Activity	NONE

Molecular Formula	HO
Molecular Weight	17.0073
Charge	-1
Count

Stereochemistry	ACHIRAL
Additional Stereochemistry	No
Defined Stereocenters	0 / 0
E/Z Centers	0
Optical Activity	NONE

Molecular Formula	Cu
Molecular Weight	63.546
Charge	2
Count

Stereochemistry	ACHIRAL
Additional Stereochemistry	No
Defined Stereocenters	0 / 0
E/Z Centers	0
Optical Activity	NONE

Description
Sources: https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=a84d61a4-8e7f-4be1-aba6-f633b334aafc | http://www.sciencedirect.com/science/article/pii/S0167488912000158https://www.ncbi.nlm.nih.gov/pubmed/16971307DOI: 10.1107/s0567740869001725 Retrived from http://scripts.iucr.org/cgi-bin/paper?S0567740869001725https://www.accessdata.fda.gov/scripts/cdrh/cfdocs/cfcfr/CFRSearch.cfm?fr=522.518 | http://www.worldofchemicals.com/chemicals/chemical-properties/cupric-glycinate.htmlhttps://www.ncbi.nlm.nih.gov/pubmed/8556785 | https://www.ncbi.nlm.nih.gov/pubmed/2135524https://www.ncbi.nlm.nih.gov/pubmed/15704330 | https://www.ncbi.nlm.nih.gov/pubmed/12425037 | https://www.ncbi.nlm.nih.gov/pubmed/1599240 | http://www.certisusa.com/pdf-labels/Kocide3000_label.pdf | http://www.pesticideinfo.org/Detail_Chemical.jsp?Rec_Id=PC33524http://www.emdmillipore.com/US/en/product/Copper-di-ammonium-Titriplex-solution,MDA_CHEM-105217http://www.drugfuture.com/chemdata/tetraamminecopper-sulfate.html | https://cameochemicals.noaa.gov/chemical/3026https://www3.epa.gov/pesticides/chem_search/ppls/019713-00509-20110705.pdfhttp://fs1.agrian.com/pdfs/CORE_7.5_Copper_EDTA_Label.pdfhttps://www.ncbi.nlm.nih.gov/pubmed/6526221http://www.ema.europa.eu/docs/en_GB/document_library/Maximum_Residue_Limits_-_Report/2009/11/WC500013010.pdfhttps://www.ncbi.nlm.nih.gov/pubmed/24106015 | https://www.ncbi.nlm.nih.gov/pubmed/20942456http://www.drugfuture.com/chemdata/schweizer-s-reagent.html | http://pubs.acs.org/doi/abs/10.1021/ed062p878?journalCode=jceda8 | http://pubs.acs.org/doi/abs/10.1021/ed019p356
Curator's Comment: description was created based on several sources, including https://www.copper.org/resources/properties/compounds/other_compounds.html | http://www.vitamins-supplements.org/dietary-minerals/copper.php | https://dailymed.nlm.nih.gov/dailymed/fda/fdaDrugXsl.cfm?setid=bea888b4-9cc6-49da-89e6-5c273b974ed1

Tetraamminecopper dihydroxide also known as Schweizer's Reagent dissolves cellulose; used in rayon production.

CNS Activity

Originator

Approval Year

Targets

Primary Target	Pharmacology	Potency
Xanthine dehydrogenase/oxidase 41 Target ID: CHEMBL1075246 Sources: https://www.ncbi.nlm.nih.gov/pubmed/3861140	Inhibitor 8297	3.42 µM [Ki]
Ceruloplasmin 35 Target ID: P00450 Gene ID: 1356.0 Gene Symbol: CP Target Organism: Homo sapiens (Human) Sources: https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=a84d61a4-8e7f-4be1-aba6-f633b334aafc	Binding Agent 1064
Glutathione S-transferase, rat, liver 35 Target ID: Glutathione S-transferase, rat, liver Sources: https://www.ncbi.nlm.nih.gov/pubmed/3008276	Binding Agent 1064
reactive oxygen species metabolic process 68 Target ID: GO:0072593 Sources: https://www.ncbi.nlm.nih.gov/pubmed/8503093	Modulator 828
Escherichia coli 82 Target ID: CHEMBL354 Sources: https://www.ncbi.nlm.nih.gov/pubmed/22098250	Inhibitor 8297

Conditions

Condition	Modality	Highest Phase	Product
Unknown 2578
Root caries 35 Sources: https://www.ncbi.nlm.nih.gov/pubmed/8556785 https://www.ncbi.nlm.nih.gov/pubmed/3201109	Preventing	Preclinical	Unknown Approved Use Unknown
Copper deficiency 35 Sources: https://www.ncbi.nlm.nih.gov/pubmed/22444781 https://www.ncbi.nlm.nih.gov/pubmed/20569928	Preventing	Preclinical	Unknown Approved Use Unknown
Copper deficiency 35 Sources: https://www.accessdata.fda.gov/scripts/cdrh/cfdocs/cfcfr/CFRSearch.cfm?fr=522.518	Preventing	Approved 8429	Cupric glycinate Approved Use Indications for use. For beef calves and beef cattle for the prevention of copper deficiency, or when labeled for veterinary prescription use, for the prevention and/or treatment of copper deficiency alone or in association with molybdenum toxicity.
Unknown 2578
Copper deficiency 35 Sources: http://www.bayeranimal.co.nz/en/product-detail.php?p=%203030	Primary	Approved 8429	COPPER•MAX Approved Use Unknown
Unknown 2578
Menkes' kinky hair disease 35 Sources: https://www.ncbi.nlm.nih.gov/pubmed/6520571 https://www.ncbi.nlm.nih.gov/pubmed/4042823 https://www.ncbi.nlm.nih.gov/pubmed/189959	Primary	Not Provided 504	Unknown Approved Use Unknown
Liver cancer 53 Sources: https://www.ncbi.nlm.nih.gov/pubmed/6526221 https://www.ncbi.nlm.nih.gov/pubmed/7326825	Preventing	Preclinical	Unknown Approved Use Unknown
Unknown 2578
Cancer 592 Sources: https://www.ncbi.nlm.nih.gov/pubmed/21039194	Primary	Preclinical	Unknown Approved Use Unknown
Cancer 592 Sources: https://www.ncbi.nlm.nih.gov/pubmed/22812694	Diagnostic	Preclinical	Unknown Approved Use Unknown
Unknown 2578
Copper deficiency 35 Sources: https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=a84d61a4-8e7f-4be1-aba6-f633b334aafc	Preventing	Approved 8429	COPPER Approved Use Copper 0.4 mg/mL (Cupric Chloride Injection, USP) is indicated for use as a supplement to intravenous solutions given for total parenteral nutrition (TPN). Administration helps to maintain copper serum levels and to prevent depletion of endogenous stores and subsequent deficiency symptoms.
Unknown 2578
Unknown 2578
Copper deficiency 35 Sources: http://www.noahcompendium.co.uk/?id=-446109	Preventing	Approved 8429	COPINOX Approved Use Copinox 4g is indicated for the prevention and treatment of copper deficiency in cattle and sheep.

PubMed

Title	Date	PubMed
Determination of protein by the biuret reaction using cupric hydroxide suspension reagent.	1960	14446699
The genetics of tasting in mice. VII. Glycine revisited, and the chromosomal location of Sac and Soa.	1995 Oct	8522158
X-ray absorption spectroscopy study of a copper-containing material after thermal treatment.	2006 Apr 17	16257485
Bioavailability of copper from copper glycinate in steers fed high dietary sulfur and molybdenum.	2008 Jan	17911232
Copper(II) acetate-catalyzed addition of arylboronic acids to aromatic aldehydes.	2009 Jan 16	19067580
Zinc prevents the copper-induced damage of cultured astrocytes.	2010 Oct	20600438
Anti-ovulatory activity of H2 receptor blockers in albino rabbits--a preliminary study.	2011 Apr	21281096
Rapid free chlorine decay in the presence of Cu(OH)2: chemistry and practical implications.	2011 Oct 15	21868051
Zeta potential and solubility to toxic ions as mechanisms of lung inflammation caused by metal/metal oxide nanoparticles.	2012 Apr	22240982
Protective effect of sulphoraphane against oxidative stress mediated toxicity induced by CuO nanoparticles in mouse embryonic fibroblasts BALB 3T3.	2012 Feb	22293418
Probing the chemical nature of dihydrogen complexation to transition metals, a gas phase case study: H2-CuF.	2013 Jan 18	23301994
Molecular responses of mouse macrophages to copper and copper oxide nanoparticles inferred from proteomic analyses.	2013 Nov	23882024
Cytotoxicity in the age of nano: the role of fourth period transition metal oxide nanoparticle physicochemical properties.	2013 Nov 25	24120544
The modality of cell-particle interactions drives the toxicity of nanosized CuO and TiO₂ in human alveolar epithelial cells.	2013 Oct 24	23906720
Effects of different sources of copper on Ctr1, ATP7A, ATP7B, MT and DMT1 protein and gene expression in Caco-2 cells.	2014 Jul	24815816
CuO nanoparticles induce apoptosis by impairing the antioxidant defense and detoxification systems in the mouse hippocampal HT22 cell line: protective effect of crocetin.	2015 Jun	25701151
Unusual 4-arsonoanilinium cationic species in the hydrochloride salt of (4-aminophenyl)arsonic acid and formed in the reaction of the acid with copper(II) sulfate, copper(II) chloride and cadmium chloride.	2017 Apr 1	28378716
Ultrasonic energy enhanced the efficiency of advance extraction methodology for enrichment of trace level of copper in serum samples of patients having neurological disorders.	2017 Jul	28427628
Effects of Excess Copper Ions on Decidualization of Human Endometrial Stromal Cells.	2017 May	27726061

Patents

Sample Use Guides

In Vivo Use Guide

Copper 0.4 mg/mL (Cupric Chloride Injection) contains 0.4 mg copper/mL and is administered intravenously only after dilution. The additive should be diluted in a volume of fluid not less than 100 mL. For the adult receiving total parenteral nutrition, the suggested additive dosage is 0.5 to 1.5 mg copper/day (1.25 to 3.75 mL/day). For pediatric patients, the suggested additive dosage is 20 mcg copper/kg/day (0.05 mL/kg/day). Infants weighing less than 1500 gm may have increased requirements because of their low body reserves and increased requirements for growth.

Route of Administration: Intravenous

In Vitro Use Guide

Human Endometrial Stromal Cells were treated with non-toxic concentrations of copper ions (0-250 uM). mRNA expressions of insulin-like growth factor binding protein (IGFBP-1), prolactin (PRL), Mn-SOD, and FOXO1 were down-regulated during decidualization following the treatments with 100 or 250 uM copper ions. Meanwhile, the amount of malonaldehyde in the supernatant of cells was increased.

Substance Class	Chemical Created by `admin` on `Fri Dec 15 16:46:57 UTC 2023` Edited by `admin` on `Fri Dec 15 16:46:57 UTC 2023`
Record UNII	5NKQ44K2RN
Record Status	`Validated (UNII)`
Record Version

Download

Name

Type

Language

TETRAAMMINECOPPER SULFATE MONOHYDRATE

Common Name

English

COPPER(2+), TETRAAMMINE-, SULPHATE (1:1), MONOHYDRATE

Common Name

English

TETRAAMMINECOPPER SULPHATE, HYDRATE

Common Name

English

CUPRIC SULFATE, AMMONIATED

Common Name

English

TETRAAMMINECOPPER(2+) SULFATE MONOHYDRATE

Common Name

English

TETRAAMMINECOPPER(II) SULFATE MONOHYDRATE

Common Name

English

CUPRUM AMMONIO-SULPHURICUM

Common Name

English

AMMONIATED CUPRIC SULFATE MONOHYDRATE

Common Name

English

TETRAAMMINECOPPER(2+) SULFATE (1:1) MONOHYDRATE

Common Name

English

COPPER TETRAAMMINE SULPHATE MONOHYDRATE

Common Name

English

AMMONIATED CUPRIC SULPHATE MONOHYDRATE

Common Name

English

CUPRUM AMMONIO-SULPHURICUM [HPUS]

Common Name

English

CUPRIC SULPHATE, AMMONIATED

Common Name

English

COPPER TETRAAMMINE SULFATE MONOHYDRATE

Common Name

English

COPPER(2+), TETRAAMMINE-, SULFATE (1:1), MONOHYDRATE

Common Name

English

COPPER(2+), TETRAAMMINE-, SULFATE, HYDRATE (1:1:1)

Common Name

English

TETRAAMMINECOPPER(2+) SULPHATE MONOHYDRATE

Common Name

English

TETRAAMMINECOPPER(2+) SULPHATE (1:1) MONOHYDRATE

Common Name

English

TETRAAMMINECOPPER SULPHATE MONOHYDRATE

Common Name

English

COPPER(2+), TETRAAMMINE-, SULPHATE, HYDRATE (1:1:1)

Common Name

English

TETRAAMMINECOPPER SULFATE, HYDRATE

Common Name

English

TETRAAMMINECOPPER(II) SULPHATE MONOHYDRATE

Common Name

English

Code System Code Type Description

FDA UNII

5NKQ44K2RN

Created by admin on Fri Dec 15 16:46:57 UTC 2023 , Edited by admin on Fri Dec 15 16:46:57 UTC 2023

PRIMARY

EPA CompTox

DTXSID70908605

Created by admin on Fri Dec 15 16:46:57 UTC 2023 , Edited by admin on Fri Dec 15 16:46:57 UTC 2023

PRIMARY

CAS

10380-29-7

Created by admin on Fri Dec 15 16:46:57 UTC 2023 , Edited by admin on Fri Dec 15 16:46:57 UTC 2023

PRIMARY

PUBCHEM

61513

Created by admin on Fri Dec 15 16:46:57 UTC 2023 , Edited by admin on Fri Dec 15 16:46:57 UTC 2023

PRIMARY

Related Record Type Details


					8CBV67279L

CUPRIC CATION

PARENT -> SALT/SOLVATE


					YMW7182547

TETRAAMMINECOPPER SULFATE

ANHYDROUS->SOLVATE

Details

SMILES

InChI

CNS Activity

Originator

Approval Year

Targets

Conditions

Approved Use

Approved Use

Approved Use

Approved Use

Approved Use

Approved Use

Approved Use

Approved Use

Approved Use

Approved Use

PubMed

Patents

Sample Use Guides